PL3909953T3 - Związek soli updacytynibu i sposób jego otrzymywania - Google Patents

Związek soli updacytynibu i sposób jego otrzymywania

Info

Publication number
PL3909953T3
PL3909953T3 PL20803029.6T PL20803029T PL3909953T3 PL 3909953 T3 PL3909953 T3 PL 3909953T3 PL 20803029 T PL20803029 T PL 20803029T PL 3909953 T3 PL3909953 T3 PL 3909953T3
Authority
PL
Poland
Prior art keywords
updacitinib
preparattion
method therefor
salt compound
salt
Prior art date
Application number
PL20803029.6T
Other languages
English (en)
Inventor
Peng Wang
Pixu Li
Qiang Wei
Wen Cheng
Original Assignee
Suzhou Pengxu Pharmatech Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Pengxu Pharmatech Co., Ltd. filed Critical Suzhou Pengxu Pharmatech Co., Ltd.
Publication of PL3909953T3 publication Critical patent/PL3909953T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
PL20803029.6T 2019-05-09 2020-05-08 Związek soli updacytynibu i sposób jego otrzymywania PL3909953T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910385804.0A CN111909160B (zh) 2019-05-09 2019-05-09 一种乌帕替尼盐类化合物及其制备方法
PCT/CN2020/089119 WO2020224633A1 (zh) 2019-05-09 2020-05-08 一种乌帕替尼盐类化合物及其制备方法

Publications (1)

Publication Number Publication Date
PL3909953T3 true PL3909953T3 (pl) 2023-11-27

Family

ID=73050727

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20803029.6T PL3909953T3 (pl) 2019-05-09 2020-05-08 Związek soli updacytynibu i sposób jego otrzymywania

Country Status (10)

Country Link
US (1) US12091414B2 (pl)
EP (1) EP3909953B1 (pl)
JP (1) JP7436057B2 (pl)
KR (1) KR20220006498A (pl)
CN (1) CN111909160B (pl)
ES (1) ES2953199T3 (pl)
HR (1) HRP20230813T1 (pl)
HU (1) HUE062473T2 (pl)
PL (1) PL3909953T3 (pl)
WO (1) WO2020224633A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220002306A1 (en) * 2018-09-29 2022-01-06 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib and preparation method and use thereof
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
JP2024514820A (ja) * 2021-04-07 2024-04-03 アッヴィ・インコーポレイテッド ウパダシチニブの共結晶
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
WO2024075131A1 (en) * 2022-10-03 2024-04-11 Natco Pharma Limited Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof
CN117447481A (zh) * 2023-12-23 2024-01-26 潍坊医学院 一种乌帕替尼-焦谷氨酸盐的无定形物及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4782062A2 (en) * 2009-12-01 2026-07-29 AbbVie Inc. Novel tricyclic compounds
CN116270646A (zh) * 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) * 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) * 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
CN110392572A (zh) * 2017-03-09 2019-10-29 艾伯维公司 治疗克罗恩病和溃疡性结肠炎的方法
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとbtkの阻害剤との組合せおよびその使用
US20220002306A1 (en) 2018-09-29 2022-01-06 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib and preparation method and use thereof
EP3891151A1 (en) * 2018-12-05 2021-10-13 LEK Pharmaceuticals d.d. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
WO2020115213A1 (en) * 2018-12-07 2020-06-11 Lek Pharmaceuticals D.D. Solvate of a selective jak1 inhibitor
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
WO2021005484A1 (en) * 2019-07-11 2021-01-14 Mankind Pharma Ltd. Pyrrolidine compounds, its salt and use in the preparation of upadacitinib thereof
BR112022012153A2 (pt) * 2019-12-19 2022-08-30 Curia Spain S A U Processo para preparar um composto e composto
WO2021244323A1 (zh) * 2020-06-05 2021-12-09 苏州科睿思制药有限公司 一种乌帕替尼的晶型及其制备方法和用途
AU2021303629A1 (en) * 2020-07-08 2023-03-09 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib, preparation method therefor, and use thereof
US20240316040A1 (en) * 2020-12-29 2024-09-26 Abbvie Inc. Extended release upadacitinib formulations

Also Published As

Publication number Publication date
HRP20230813T1 (hr) 2023-11-24
US20220041611A1 (en) 2022-02-10
EP3909953A4 (en) 2022-05-04
EP3909953B1 (en) 2023-06-07
JP2022534551A (ja) 2022-08-02
KR20220006498A (ko) 2022-01-17
HUE062473T2 (hu) 2023-11-28
CN111909160B (zh) 2024-05-28
EP3909953A1 (en) 2021-11-17
JP7436057B2 (ja) 2024-02-21
CN111909160A (zh) 2020-11-10
WO2020224633A1 (zh) 2020-11-12
EP3909953C0 (en) 2023-06-07
US12091414B2 (en) 2024-09-17
ES2953199T3 (es) 2023-11-08

Similar Documents

Publication Publication Date Title
GB201907244D0 (en) Method
HUE062473T2 (hu) Updacitinib só vegyület és eljárás elõállítására
IL290692A (en) Salt
GB201913997D0 (en) Method
GB201911286D0 (en) Method
GB201909562D0 (en) Method
GB201917742D0 (en) Method
GB201910759D0 (en) Method
GB201917638D0 (en) Method
GB201917060D0 (en) Method
GB201907782D0 (en) Method
GB201900940D0 (en) Method
GB201900647D0 (en) Method
GB201906768D0 (en) Method
IL289648A (en) method
GB201917824D0 (en) Method
GB201913970D0 (en) Method
GB201910404D0 (en) Method
GB201909131D0 (en) Method
GB201906203D0 (en) Method
GB201901532D0 (en) Method
GB202007297D0 (en) Method
GB2587925B (en) Method
GB201918290D0 (en) Method
GB201917806D0 (en) Method